The SEC's complaint alleges that, between April 9 and 11, 2023, Xie-then the Director of Analytical Development at BELLUS Health-learned that GSK was conducting due diligence of BELLUS Health and helped respond to GSK's due diligence questions. The complaint further alleges that, between April 12 and 17, 2023, Xie purchased 7,051 BELLUS Health shares and 100 short-term, out-of-the-money call options that allowed him to purchase another 1,000 BELLUS Health shares. On April 18, 2023, GSK's acquisition of BELLUS Health was publicly announced and the price of BELLUS Health stock rose by approximately 99%, allegedly generating ill-gotten gains of $59,408.42 for Xie. /jlne.ws/48cC1oW